Tempest Therapeutics, Inc. Files Form 8-K: Overview and Key Shareholder Considerations
Tempest Therapeutics, Inc. (NASDAQ: TPST), a clinical-stage oncology company based in Brisbane, California, has filed a Form 8-K with the Securities and Exchange Commission (SEC) dated May 22, 2026. This filing provides several updates that shareholders and potential investors should be aware of.
Key Points from the Filing
- Form Type: 8-K (Current Report)
- Date of Report: May 22, 2026
- Trading Symbol: TPST
- Exchange: The Nasdaq Stock Market LLC
- SEC File Number: 001-35890
- Business Address: 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005
- Former Company Names: Millendo Therapeutics, Inc. (name changed 2018), OvaScience, Inc. (name changed 2012)
- Emerging Growth Company Status: No
Important Shareholder Information and Price-Sensitive Details
- No Amendment: The filing is not an amendment to any prior submission (Amendment Flag: false).
- Securities Registered:
- Common Stock, \$0.001 par value (Trading Symbol: TPST, registered on NASDAQ)
- Series A Junior Participating Preferred Purchase Rights (also registered on NASDAQ, but no trading symbol assigned)
- Communications:
- No written communications pursuant to Rule 425 under the Securities Act (i.e., no merger or acquisition communications).
- No soliciting material under Rule 14a-12, nor any pre-commencement communications under Rules 14d-2(b) or 13e-4(c).
- Indemnification and Separation Agreements:
- The report references the company’s non-employee director compensation program and Separation Agreements for certain directors. These agreements ensure that departing directors are paid any accrued and unpaid fees, and their rights under existing stock option awards or equity ownership remain unaffected.
- Importantly, indemnification agreements for these directors will remain in effect for six years following their separation. The underlying rights in the company’s charter and bylaws are unchanged. This may be relevant for shareholders interested in governance and continuity.
- The full texts of these agreements will be filed as exhibits in the company’s upcoming Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
Potential Share Price Impact
- No Immediate Price-Sensitive Announcements: This 8-K does not announce new product developments, financings, M&A activity, leadership changes, or other major events likely to directly move Tempest Therapeutics’ share price in the immediate term.
- The reference to director separation agreements and indemnification is a matter of routine corporate governance and does not indicate any dispute or extraordinary event that might affect investor confidence or the share price.
- There is also no indication of changes to the company’s strategy, operations, or financial condition in this filing.
Summary
Tempest Therapeutics’ latest 8-K filing is largely administrative, dealing with standard corporate governance disclosures. There are no new business, financial, or strategic disclosures that would be considered material or likely to move the company’s share price at this time. Shareholders should note that all director indemnification and compensation matters are being handled according to established company procedures, with no adverse changes reported.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor before making any investment decisions related to Tempest Therapeutics, Inc. or any other security. The author and publisher do not hold any position in the securities mentioned in this article at the time of publication.
